Table 1.

Clinical characteristics of seven patients with alterations in liver function treated with tocilizumab.

Variable	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Age-year	44	73	61	56	51	71	59
CRP-mg/dl	262	395	242	91	283	116	361
D-dimer-ng/ml	808	3581	1382	753	509	15169	710
IL-6 (pg/ml)	88,5	159,7	37,3	27,6	112,1	n.a.	270
Tocilizumab dosage (mg)	640	800	720	600	600	800	560
AST (UI/l)
Admission	35	31	26	65	29	33	51
Before Tocilizumab (T0)	78	105	93	122	189	97	99
1 week later	37	50	55	53	36	29	26
3 weeks later	26	23	22	35	39	17	26
ALT (UI/l)
Admission	47	43	30	118	30	36	36
Before Tocilizumab (T0)	128	49	100	199	118	120	49
1 week later	118	43	57	79	84	54	39
3 weeks later	51	38	30	40	35	28	54
GGT (UI/l)
Admission	21	41	181	86	102	60	33
Before Tocilizumab	60	35	420	118	338	119	89
1 week later	23	58	50	72	167	89	81
3 weeks later	18	54	27	21	41	30	16

Reference ranges are as follows: AST 2–40 U/L, ALT 2–40 U/L, GGT 10–55 U/L, CRP 0.5–5 mg/dl, IL6 0,5–3 pg/ml, D-dimer 0–300 mg/dl.

ALT, alanine aminotransferase; AST, ; aspartate aminotransferase CRP, C-reactive protein; GGT, Gamma-glutamyl transpeptidase; IL, interleukin.